Variations in the Hemostatic System Induced by a Standardized Walking Test
Launched by CENTRE HOSPITALIER UNIVERSITAIRE DE NĪMES · May 13, 2024
Trial Information
Current as of March 14, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a walking test affects the blood clotting system in two different groups of people: those who have had a history of venous thromboembolism (which includes conditions like blood clots in the veins or lungs) and those who have not. The goal is to see if there are any differences in how their bodies respond to the walking test. Participants will undergo a 60-minute walking test, and their heart activity will be monitored with an electrocardiogram, along with blood tests to measure different factors related to blood clotting.
To be eligible for this study, you need to be between 65 and 74 years old and must have given written consent. If you have a history of venous thromboembolism, your last incident must have occurred more than six months ago. On the other hand, if you do not have a history of blood clots, you should not have any family history of such conditions either. Participants should be able to walk for an hour and not have any serious health issues that would prevent them from doing so. This trial is currently recruiting, and all participants will be treated with care and respect throughout the process.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Inclusion criteria common to both groups :
- • Patients who have given written informed consent.
- • Patients who are affiliated to or beneficiaries of a social security scheme.
- Inclusion criteria specific to the Patient Group:
- • Patients with a personal history of provoked venous thromboembolism, venous thrombosis and/or pulmonary embolism, with the last attack dating back to more than 6 months, and whose clinical phenotype did not justify long-term antithrombotic drug prophylaxis.
- Definition of provoked venous thromboembolism : The clinical criteria used to classify venous thromboembolism as provoked are :
- • First year of combined oestrogen-progestogen oral contraception, or contraception using an oestrogen-impregnated vaginal ring or transcutaneous synthetic oestrogen patch.
- • Hormonal stimulation for oocyte retrieval
- • Pregnancy and 6 weeks post-partum
- • Surgery
- • Trauma
- • Immobilisation in plaster or splint
- • Outbreak of acute infectious disease
- • Acute flare-up of inflammatory disease
- • Prolonged air travel lasting at least 4 hours
- • Prolonged strict bed rest lasting at least 3 consecutive days.
- Inclusion criteria specific to the Control Group:
- • Subjects with no personal history of venous thromboembolism
- • Subjects with no family history of venous thromboembolism in first-degree relatives
- • Subjects of the same sex and age with a tolerance of +/- 5 years in relation to the matched case.
- Exclusion Criteria:
- • Patients who are physically unable to perform the 60-minute walking test, for any reason, in particular cardiovascular contraindications to exercise (recent acute coronary syndrome unstable angina, rhythm disorders, tight aortic stenosis, cardiac heart failure, acute myocarditis, pericarditis or endocarditis endocarditis, poorly controlled hypertension, pre-stress blood pressure \> 200/110 mmHg, recent stroke or transient ischemic attack).
- • Patients on anticoagulant or antithrombotic treatment, ongoing or discontinued within the last month.
- • Patients treated for pulmonary embolism who remain dyspneic after anticoagulant treatment and requiring a work-up for pulmonary hypertension.
- • Last surgery dating back to less than 3 months.
- • Known chronic morbidities: diabetes mellitus, chronic inflammatory or infectious disease, heart failure, renal insufficiency, hepatic insufficiency or arterial thrombosis dating back to less than 3 months.
- • For women: treatment containing synthetic or natural estrogen, in progress or discontinued for less than a month
- • Pregnancy within the last year.
- • Difficult venous access.
- • Regular practice of an intensive sporting/physical activity, such as running, tennis, cycling etc. of more than 3 hours per week.
Trial Officials
Antonia PEREZ MARTIN, Prof.
Principal Investigator
Nîmes University Hospital
Stéphane FAURE
Principal Investigator
Nîmes University Hospital
About Centre Hospitalier Universitaire De Nīmes
The Centre Hospitalier Universitaire de Nîmes (CHU Nîmes) is a leading academic medical center located in Nîmes, France, dedicated to advancing healthcare through innovative clinical research and patient care. As a prominent sponsor of clinical trials, CHU Nîmes collaborates with a multidisciplinary team of healthcare professionals and researchers to conduct rigorous studies aimed at improving treatment outcomes and enhancing medical knowledge across various specialties. With a strong commitment to ethical standards and patient safety, CHU Nîmes fosters a research environment that encourages scientific excellence and contributes to the development of new therapies and healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nîmes, Occitanie, France
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0